Related Experiment Videos
IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction
L Carrington1, D McLeod, M Boulton
1Department of Optometry and Vision Sciences, University of Cardiff, United Kingdom.
Investigative Ophthalmology & Visual Science
|February 7, 2001
Summary
Platelet-derived growth factor (PDGF) and transforming growth factor-beta2 (TGF-beta2) significantly contribute to retinal pigment epithelial (RPE) cell-mediated contraction in proliferative vitreoretinopathy (PVR). Neutralizing antibodies targeting PDGF and TGF-beta2 effectively inhibit this contraction, offering potential therapeutic strategies for PVR.
Area of Science:
- Ophthalmology
- Cell Biology
- Regenerative Medicine
Background:
- Retinal pigment epithelial (RPE) cells are implicated in epiretinal membrane formation and contraction in proliferative vitreoretinopathy (PVR).
- Understanding the role of growth factors in RPE cell-mediated retinal contraction is crucial for developing PVR therapies.
Purpose of the Study:
- To investigate the contribution of various growth factors to human RPE cell-mediated retinal contraction using an organ culture model mimicking PVR.
- To assess the efficacy of neutralizing antibodies against specific growth factors in inhibiting RPE-mediated retinal contraction.
Main Methods:
- Human RPE cells were cultured on bovine retinal explants.
- Exogenous growth factors (PDGF-AB, PDGF-BB, bFGF, TGF-beta1, TGF-beta2, IL-10) or neutralizing antibodies were applied.
- Retinal contraction was quantified via image analysis as a percentage reduction in retinal area.
Main Results:
- Untreated RPE cells caused over 50% retinal contraction within 7 days.
- PDGF and TGF-beta2 significantly enhanced RPE-mediated contraction.
- Interleukin-10 (IL-10) reduced contraction by 63%; neutralizing antibodies against PDGF and TGF-beta2 inhibited contraction by up to 70%.
Conclusions:
- Platelet-derived growth factor (PDGF) and transforming growth factor-beta2 (TGF-beta2) play significant roles in RPE cell-mediated retinal contraction.
- Neutralizing antibodies against PDGF and TGF-beta2, along with IL-10, show promise as therapeutic agents for inhibiting PVR contraction.